Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

3(42.9%)

7Total

Phase 2(4)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07450859Phase 2Recruiting

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

NCT06225596Phase 2Active Not Recruiting

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Role: lead

NCT06933329Phase 2Active Not Recruiting

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

Role: lead

NCT06840483Phase 2Active Not Recruiting

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Role: lead

NCT05163041Phase 1Active Not Recruiting

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Role: lead

NCT04180371Phase 1Active Not Recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Role: lead

NCT04561362Phase 1Active Not Recruiting

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Role: lead

All 7 trials loaded